Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To assess the occurrence of dopaminergic adverse-events (AEs) in levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients when starting opicapone (OPC) 50mg or entacapone (ENT). Background:…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a new once-daily COMT…Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone (OPC)…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a novel once-daily…ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
Objective: To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…Decision-making process for opicapone’s bedtime regimen
Objective: To clarify the decision-making process for opicapone’s bedtime regímen. Background: OPC, a new once-daily COMT inhibitor, was shown to be effective in the treatment…ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)
Objective: The PD MED trial aimed to determine which class of drug provides the best patient-rated quality of life (QoL) when used as adjuvant therapy…